Related by context. All words. (Click for frequent words.) 86 Presents Positive 83 Receives Milestone Payment 82 Receives Approvable Letter 81 Reports Positive 81 Completes Patient Enrollment 81 Submits Biologics License Application 81 Presents Preclinical 80 Initiates Clinical Trial 80 Receives Orphan Drug Designation 80 Initiates Enrollment 80 Completes Enrollment 80 Begins Dosing 79 Initiates Phase III 79 Cites Positive 79 Presents Positive Preclinical 79 Initiates Phase II 79 Presents Preclinical Data 78 Submits NDA 78 Announces Positive 78 Licenses Novel 78 Announces Presentation 78 Files IND 77 Earns Milestone Payment 77 Therapeutic Competitors Companies 77 Receives Fast Track 77 Submits Response 77 Announce License Agreement 77 Drug Fails 77 Q4 Loss Narrows 77 Initiates Clinical 76 Gets FDA Clearance 76 Jumps Higher 76 IG HCR ;) CO 76 Arthritis Drug 76 Meets Primary Endpoint 76 FDA Clears 76 Net Loss Narrows 76 Demonstrates Positive 76 Q3 Loss Narrows 76 Receives Orphan Drug 76 Present Preclinical Data 76 Phase 2b Clinical Trial 75 Q3 Loss Widens 75 Receives Tentative Approval 75 Receives Favorable 75 Enrolls First 75 Lupus Drug 75 Posts Wider Loss 75 Q2 Loss Narrows 75 Q1 Loss Narrows 75 Shows Promising 75 Announces Initiation 75 Announces Tentative Approval 75 Initiates Clinical Trials 75 Receives Positive 75 Q1 Adj 75 Q4 Loss Widens 75 Q1 Loss Widens 74 Licenses Patents 74 Receives Complete Response 74 Net Loss Widens 74 Announce Licensing Agreement 74 Submits IND 74 Sinks Lower 74 Q2 Profit Surges 74 Receives Positive Opinion 74 Patient Enrollment 74 Files Shelf Registration Statement 74 Announce Collaboration Agreement 74 Receive Milestone Payment 74 Q2 Loss Widens 74 Demonstrates Significant 74 Announces FDA Clearance 74 Terminate Merger Agreement 74 Achieves Primary Endpoint 74 Submits Application 74 Reports Preclinical Data 74 Initiates Dosing 74 Drug Candidate 74 Sign Licensing Agreement 74 Submits Supplemental 74 Collaborators Present 73 Launches Generic Version 73 FDA Okays 73 Biogen Genentech 73 Sign License Agreement 73 Successfully Completes Tender Offer 73 BioSante Pharmaceuticals Announces 73 Completes Dosing 73 Begins Clinical Trial 73 Announces Favorable 73 Significantly Improves 73 Q2 Adj 73 Novartis Novo Nordisk 73 Guides Below 73 PRN FDA Approves 73 Posts Narrower Loss 73 Q1 Profit Surges 73 Posts Wider 73 Phase IIb Trial 73 Psoriasis Drug 73 Provides Preliminary 73 Milestone Payment 73 Investigational Compound 73 Successfully Completes Phase 73 Inc. Nasdaq OXGN 73 Receives FDA Clearance 73 Announces Publication 73 Rheumatoid Arthritis Drug 73 Updates Guidance 73 Welcomes Analyst Initiation 73 Lowers Guidance 72 Guides Inline 72 Significantly Reduces 72 Namenda Memantine HCl 72 Stays Neutral 72 Schizophrenia Drug 72 Phase 2a Trial 72 Extends Collaboration 72 Settle Patent Litigation 72 Drug Shows Promise 72 Achieves Milestone 72 Clinical Trial Results 72 Earnings Postmortem 72 Reaffirms Outlook 72 Inc Therapeutic Competitors 72 Genentech sanofi aventis 72 Q4 Profit Surges 72 Shares Soar 72 Osteoporosis Drug 72 Q3 Profit Surges 72 Improves Survival 72 Therapeutic Competitors companiesandmarkets.com adEgemonye 72 Reconfirms 72 Vaccine Adjuvant 72 Guides Above 72 Webcast Presentations 72 Granted Orphan Drug 72 Announces Licensing Agreement 72 Receives Unsolicited 72 Initiates Phase 72 Settle Patent Dispute 72 Q3 Adj 72 Bullish Average Crossover 72 VIVUS Announces 72 Initiates Phase 2b 72 Reports Narrower 72 Provides Guidance 72 Q2 Profit Declines 72 please visit http:/www.vandapharma.com 72 Remains Neutral 72 Q2 Profit Rises 71 Completes Patient Enrolment 71 Epilepsy Drug 71 Immunomedics Announces 71 Q1 Profit Rises 71 Obtains FDA 71 Initiate Phase III 71 Posts 2Q 71 Phase III Trial 71 Puts Purchased 71 Voluntarily Withdraw 71 Revises Guidance 71 Announces Dosing 71 Raises Guidance 71 Posts Strong 71 Q4 Profit Plunges 71 Merck OSI Pharmaceuticals 71 1Q Loss Widens 71 Lung Cancer Drug 71 Narrows Guidance 71 Shows Promise 71 Phase III Clinical Trial 71 Commences Phase 71 Amends Agreement 71 Announces License Agreement 71 FDA Accepts 71 Shares Surge 71 Collaborators Publish 71 Ups Guidance 71 Successfully Completes Acquisition 71 Expects Higher 71 Develop Novel 71 FDA Approvals 71 Regains Full 71 Receives Notification 71 Preliminary Second Quarter 71 Completes Tender Offer 71 Combination REOLYSIN R 71 Plans Job Cuts 71 Gout Drug 71 Initiate Clinical Trial 71 Generic Versions 71 Cholesterol Drug 71 Announce Merger Agreement 71 Refractory Hodgkin Lymphoma 71 4Q Loss Widens 71 Novel Oral 71 Q4 Profit Soars 71 Reaffirms Guidance 71 Receives SFDA Approval 71 Board Unanimously Rejects 71 Hold Fourth Quarter 71 3Q Loss Narrows 71 Q1 Profit Declines 71 Pivotal Phase III 71 Achieves Positive 71 Posts Solid 71 visit www.sciclone.com 71 Receives Anticipated 71 Misses Expectations 71 Significantly Increases 71 Provides Updated 71 Shows Efficacy 71 Announce Initiation 71 Posts 4Q 71 Mylan Receives Approval 71 widens Quick Facts 71 Preclinical Data 71 Phase IIb Clinical Trial 71 narrows Quick Facts 70 Q4 Profit Declines 70 Improves Outcomes 70 Movers Roundup 70 Above Estimates 70 Calls Purchased 70 Announces Preliminary 70 Completes Merger With 70 Q3 Profit Declines 70 Invites Investors 70 Q4 Adj 70 Guides Q4 70 Shareholders Approve Acquisition 70 Genentech Wyeth Pharmaceuticals 70 Announces Successful Completion 70 Announces Discontinuation 70 Shares Plummet 70 TM Aganocide 70 Announces Poster Presentations 70 Extends Tender Offer 70 2Q Loss Widens 70 Earnings Surge 70 Settles Patent Dispute 70 Post Earnings Checkup 70 please visit http:/www.atherogenics.com 70 NewsBite Downgrade Puts Pressure 70 Provides Update Regarding 70 Signs License Agreement 70 Awarded Patents 70 Regains NASDAQ 70 NDA Submission 70 Stockholders Approve Merger 70 Migraine Drug 70 FDA Approves 70 PROFILE CO 70 Bearish Speculation 70 Nasdaq PGNX 70 Meets Estimates 70 4Q Loss Narrows 70 Oral Calcitonin 70 Canaccord Genuity Reiterates Buy 70 Earnings Scorecard 70 Issues Guidance 70 Loss Shrinks 70 4Q Profit Jumps 70 Buy Privately Held 70 Phase 2b Trial 70 Canaccord Genuity Maintains Hold 70 Prostate Cancer Vaccine 70 Earnings Decline 70 Receives Subpoena 70 Expand Collaboration 70 Forecast Quick Facts 70 Explore Strategic Alternatives 70 Receives Patent 70 Bullish Speculation 70 Bullish Technical Alert 70 lead molecular radiotherapeutic 70 Beats Raises Guidance 70 JAK2 Inhibitor 70 Q3 Profit Soars 70 More Than Doubles 70 Bearish Average Crossover 70 Single Dose 70 Guides Q2 70 Taro Receives 70 R MSCRAMM 70 Receives NASDAQ 70 Posts Higher 70 Inc. www.micromet inc.com 70 1Q Loss Narrows 70 Cholesterol Lowering Drug 70 3Q Profit Drops 69 FDA Panel Recommends 69 Receives Approvals 69 Maintains Buy Rating 69 4Q Profit Surges 69 Antitumor Activity 69 Bearish MACD 69 WeissComm Partners +#-#-#-# 69 Commences Phase III 69 Telik logo TELINTRA 69 Exercises Option 69 Delivers Strong 69 Gets Bearish Confirmation 69 Posts 1Q 69 Q2 Profit Plunges 69 Q3 Profit Rises 69 Below Consensus 69 Analyst Upgrade 69 Delivers Solid 69 Beats Views 69 Expands Portfolio 69 please visit www.dyax.com 69 Reduces Risk 69 Pivotal Study 69 Conference Call TRANSCRIPT 69 Restate Financial 69 Tops Ests 69 Blood Pressure Drug 69 Cuts FY# 69 visit www.genenews.com 69 Sees Positive 69 Host Fourth Quarter 69 Patients Treated With 69 Xcytrin R 69 Raises Outlook 69 Receives Clearance 69 1Q Profit Falls 69 estrogen receptor beta agonist 69 FY# Loss Widens 69 Strengthens Position 69 Novartis Organon 69 INDICATED LOWER 69 Announce Receipt 69 Settles Litigation 69 Posts Narrower 69 Advanced Melanoma 69 Merck Serono Nycomed 69 Announce Early Termination 69 Inc AMGN AMGN 69 TRACON Pharmaceuticals 69 Loss Narrows 69 Receives CE Marking 69 Misses Estimate 69 Boosts Estimates 69 Posts 4Q Profit 69 Posts Profit 69 SWOT Analysis Aarkstore Enterprise 69 Raises PT 69 IND Filing 69 Boehringer Ingelheim MedImmune 69 Guides Q1 69 4Q Profit Soars 69 Appoints Seasoned 69 Record Third Quarter 69 Receives Delisting Notification 69 Puts Sold 69 Nasdaq ZGEN 69 Backs FY# Outlook 69 Grants Orphan Drug 69 Stockholders Approve Acquisition 69 Q1 Profit Soars 69 Sanofi Aventis Schering Plough 69 Beats Forecast 69 Initiate Phase 69 Webcast Annual Meeting 69 FY# Loss Narrows 69 Announces Divestiture 69 Beats Estimates 69 Posts Smaller 69 Previously Treated 69 Flamel Technologies Announces 69 Announce Collaboration 69 Voluntarily Withdraws 69 VP Exercises Options 69 Posts Wider Than Expected 69 Skymark Research Initiates Independent 69 Signs Licensing Agreement 69 Phase IIa Clinical Trial 69 Outlook Disappoints 69 Reacquires 69 Reiterates Guidance 69 Sirna Therapeutics StrataCom 69 Receives Favorable Ruling 69 Reaffirms FY# Outlook 69 1Q Profit Up 69 Closes Acquisition Of 69 Moving Average Crossover Alert 69 Confirms Receipt 69 Amend Merger Agreement 69 First Patient Enrolled 69 Q1 Profit Plunges 69 Revenues Decline 69 visit http:/www.PAREXEL.com 69 Reduces Workforce 68 Tops Q4 68 developing ACAPODENE 68 Reports Receipt 68 Announces Adjournment 68 Fourth Quarter Earnings Preview 68 Beat Expectations 68 Revises Q4 68 2Q Profit Up 68 Releases Second Quarter 68 please visit http:/www.supergen.com 68 Tops Estimates 68 Above Consensus 68 Prolongs Survival 68 Shares Plunge 68 Releases Third Quarter 68 Study Demonstrates 68 Q2 Profit Climbs 68 Tops Expectations 68 Record Fourth Quarter 68 Reaffirms Fourth Quarter 68 Host Third Quarter 68 Begins Shipment 68 2Q Loss Narrows 68 Study Showed 68 Receives Tentative FDA 68 Q4 Profit Rises 68 FDA Warns 68 Q2 Profit Soars 68 Announces Stockholder Approval 68 Tops Estimate 68 Sangamo BioSciences Announces 68 Therapeutic Competitors 68 Crofelemer budesonide foam 68 pralatrexate injection folate analogue 68 Director Exercises Options 68 FDA Approves Generic 68 Q4 Profit Decreases 68 Nearly Triples 68 Files Patent Application 68 Shareholders Approve Merger 68 Lifts FY# Outlook 68 Acquires Exclusive 68 Attracting Bullish Investors 68 Phase 1b Clinical Trial 68 Extends Expiration Date 68 Investigational Oral 68 Sentiment Snapshot 68 Board Authorizes 68 Posts Third Quarter 68 Shares Slump 68 Oncology Compounds 68 Regains Compliance With 68 Sees Higher 68 Data Suggest 68 4Q Profit Slips 68 Sees 2Q 68 3Q Profit Rises 68 Receives Delisting Notice 68 Spectrum Pharmaceuticals Announces 68 Deliver Presentation 68 Announce Expiration 68 Q1 Profit Decreases 68 HCV Protease Inhibitor 68 CFO Resigns 68 4Q Profit Down 68 markets COLAZAL 68 Pharma Merck Serono 68 Earnings Cheat Sheet 68 Introduces Novel 68 Reports Significantly Improved 68 Clinical Trial Evaluating 68 Aftermarket Movers 68 Obtains Approval 68 Below Estimates 68 Surpasses Estimates 68 Anemia Drug 68 Beats Expectations 68 Receives Regulatory 68 Record Second Quarter 68 Second Quarter Profit Rises 68 Hold Third Quarter 68 1Q Profit Triples 68 3Q Loss Widens 68 Preliminary Fourth Quarter 68 3Q Profit Up 68 Pending Acquisition 68 Resumes Coverage 68 Beat Estimates 68 Strengthens Leadership 68 4Q Profit Drops 68 Investigational Treatment 68 Secures Financing 68 Unveils Latest 68 Receives Notice Related 68 Reiterates Buy 68 Guides Q3 68 Initiates Voluntary Recall 68 Approve Merger 68 SIX RO ROG 68 Announces Postponement 68 please visit www.abraxane.com 68 More Than Triples 68 Announces Departure 68 Trims Loss 68 Vitrasert R 68 Reveals Receipt 68 Files Investigational 68 Posts 1Q Profit 68 Boosts Guidance 68 Successfully Closes 68 ExxonMobil Fluor 68 Blood Thinner 68 Reports Narrower Loss 68 Hsp# Inhibitor 68 Study Evaluating 68 Restate Financials 68 Sees Strong 68 Achieves Record Sales 68 Announces Organizational Changes 68 sanofi aventis Bayer Schering 68 Shareholders Approve Merger Agreement 68 Earnings Rise 68 Q2 Profit Drops 68 First Patient Treated 68 Posts Fourth Quarter 68 Discontinues 68 4Q Profit Up 68 Fast Track Status 68 Generic Version 68 STERIS Corporation Announces 68 Misses Q4 68 Delays Filing 68 Stock Soars 68 Posts Wider 4Q Loss 68 Affirms FY# 68 Stock Plummets 68 pharmacogenomic translational research 68 Host Webcast 68 Unanimously Recommends Approval 68 Shares Climb 68 Boosts Quarterly Dividend 68 4Q Profit Falls 68 SVP Exercises Options 68 Trims Outlook 68 NASDAQ IDIX 68 Lowers FY# 68 Posts 4Q Loss 68 AUDIO PROVIDED BY 68 Corp. NASDAQ CYTR 68 3Q Profit Falls 68 Colaris Colaris AP 68 Boosts Dividend 68 Provides Shareholder 68 Pegloticase 68 Completes Transaction 68 Narrows 4Q Loss 68 Anemia Drugs 68 Q1 Profit Drops 68 candidates Azedra TM 68 Announce Definitive Agreement 68 Receives Conditional 67 Pivotal Phase 67 Enters Oversold Territory 67 Slashes Guidance 67 Finalizes Sale 67 Posts 3Q 67 Myriad logo BRACAnalysis 67 Strengthens Balance Sheet 67 Losses Narrow 67 CybeRelease Decliners 67 Regains Compliance 67 Successfully Treated 67 visit www.targanta.com 67 Trial Evaluating 67 Sees 1Q 67 StockPreacher.com Issues Trading 67 Long Term Efficacy 67 Recommends Approval 67 Broadens Its 67 Topline Results 67 Boosts Outlook 67 please visit www.medicinova.com 67 Newly Diagnosed Multiple Myeloma 67 Receives Notice 67 novel orally inhaled 67 2Q Profit Down 67 Study Indicates 67 2Q Profit Climbs 67 MBRX 67 Hikes Dividend 67 Drug Maker 67 Announces Revised 67 Revises FY# Outlook 67 Nasdaq IDIX 67 Unsolicited Proposal From 67 2Q Profit Rises 67 Explores Strategic Alternatives 67 Lifts Dividend 67 Inc. Nasdaq TRMS 67 Reports Profitable 67 please visit http:/www.avastin.com 67 Bearish Pressure Building 67 Approaching Resistance 67 Benzinga Volume Movers 67 Phase 2a Study 67 Stock Plunges 67 developing ostarine selective 67 Posts Quarterly 67 COO Exercises Options 67 Declares Quarterly Dividends 67 Narrows Loss 67 Pooled Analysis 67 2Q Profit Surges 67 palonosetron hydrochloride Injection Dacogen 67 Guidance Quick Facts 67 Inhaled Insulin 67 Profit Slips 67 Reaffirms FY# EPS 67 Identifies Potential 67 Corp. AMEX CVM 67 Beats Forecasts 67 Obtains License 67 Host Second Quarter 67 Pharmacyclics Announces 67 Provides Updates 67 Backs FY# EPS 67 Announces Additions 67 Showed Significant 67 Nasdaq CTIC 67 Demonstrates Potential 67 Reiterates Buy Rating 67 Increases Risk 67 Lowers Q4 67 Launches Next Generation 67 Aeolus Pharmaceuticals Announces 67 4Q Profit Doubles 67 Reaffirms Full 67 Receives Deficiency Letter 67 Nasdaq ONXX 67 Settles Patent Litigation 67 Antibody Drug Conjugate 67 Genentech GlaxoSmithKline 67 Canaccord Genuity Maintains Buy 67 Plicera TM 67 Lowers Outlook 67 Completes Purchase Of 67 Options Trader Alert 67 Introduces Next Generation 67 Boosts Profit 67 Up Sharply 67 Sees 3Q 67 Raises Forecast 67 Beats Consensus 67 Significantly Improved 67 Preliminary Third Quarter 67 Profit Beats Estimates 67 Aztreonam Lysine 67 Introduces Expanded 67 Lowers Estimates 67 platform HDL Mimetic 67 Posts Lower 67 Inc. Attracting Bullish 67 Anti Tumor 67 Loss Widens 67 Finalizes Purchase 67 Sweetens Bid 67 Dyax logo 67 Taglich Brothers Initiates Coverage 67 Ondansetron Orally Disintegrating Tablets 67 Gets Approval 67 Wins Approval 67 Combo Therapy 67 Expanded Indication 67 markets Testim ® 67 Nasdaq XTLB 67 1Q Profit Surges 67 Beats Analyst 67 Announces Early Termination 67 Weight Loss Drug 67 Milestone Payment From 67 Announces Commencement 67 Downtrend Spotted 67 Strengthens Its 67 Q4 Profit Drops 67 Takeda Kyowa Hakko Kirin 67 programs visit http:/www.bionovo.com 67 Commercialize Novel 67 Maintains Strong 67 Provides Detailed 67 Boosts Qtr 67 Q3 Profit Plunges 67 Demonstrates Statistically Significant 67 Shows Promise Against 67 Announces Stock Repurchase 67 Reports Sharply Higher 67 Narrows 1Q 67 Announces Definitive Agreement 67 Restates Earnings 67 Brentuximab Vedotin SGN 67 Files Annual Report 67 R lenalidomide 67 3Q Profit Jumps 67 Seeks Approval 67 Partnering Agreements 67 Revenue Climbs 67 From Cont 67 PPD Declares 67 Has Re Crossed 67 Profit Dips 67 Updates Fourth Quarter 67 Desvenlafaxine Succinate 67 Announces Termination 67 Expand Relationship 67 Univest Corporation Declares 67 3Q Profit Surges 67 Aradigm Logo 67 markets HP Acthar 67 Bristol Myers Squibb Celgene 67 Q1 Profit Jumps 67 Declares Preferred 67 Survival Benefit 67 Q3 Profit Drops 67 Wider Than Expected 67 Vicriviroc 67 visit http:/www.mannkindcorp.com 67 Lifts FY# Revenue 67 Profits Jump 67 1Q Profit Rises 67 Preclinical Study 67 Host Teleconference 67 Lifts FY# 67 Stockholders Approve 67 CEO Exercises Options 67 Identifies Key 67 Wider Loss 67 gets USFDA nod 67 Confirmatory Phase 67 Q4 Profit Climbs 67 OTC BB PVCT 67 Transdermal Patch 67 Discuss Second Quarter 67 Activity Alert 67 1Q Profit Jumps 67 Pruvel TM 67 Extends Offer 66 TriCo Bancshares Announces 66 Meets Expectations 66 Stock Upgraded 66 Exploring Strategic Alternatives 66 Receives Approval 66 Exceeds Estimates 66 Release Fourth Quarter 66 Webcast Second Quarter 66 please visit www.astrazeneca.com 66 please visit http:/www.astrazeneca-us.com 66 Announces Upcoming 66 UBS Maintains Neutral 66 Withdraws Application 66 Volume Spikes 66 2Q Profit Drops 66 Quadruples 66 Options Brief 66 Declares Qtr 66 Systemic Delivery 66 Further Strengthens 66 ASE SVA 66 Results Disappoint 66 Achieves Profitability 66 Closes Previously Announced 66 Options Activity 66 Completes Previously Announced 66 Generic Version Of 66 Announces Webcast 66 Updates Status 66 Revises Fourth Quarter 66 Onyx Pharmaceuticals Announces 66 advanced compound INCB# 66 CFO Exercises Options 66 please visit www.middlebrookpharma.com 66 EVP Exercises Options 66 Adjunctive Therapy 66 Million Milestone Payment 66 Enters Into Licensing Agreement 66 Nicotine Vaccine 66 Endures Analyst Downgrade 66 Introduces Enhanced 66 NASDAQ MNKD focuses 66 Inc FRX 66 Inc FRX FRX 66 Adjuvant Treatment 66 Increases Guidance 66 More Than Doubled 66 Beats Estimates Analyst Blog 66 Milestone Payments 66 1Q Profit Drops 66 Penwest Pharma 66 PFE PFE 66 initiated Phase Ib 66 Q1 Profit Dips 66 Obtains Exclusive Rights 66 Reminds Shareholders 66 Terminates Contract 66 Schedules 2Q 66 Tops Views 66 Phase III Trials 66 Guides FY# EPS 66 Profit Grows 66 Awarded Patent 66 NASDAQ ENMD 66 Posts 3Q Profit 66 Movers roundup 66 Announces Dismissal 66 Sellers Distribute Shares 66 Completes Merger 66 Beats Zacks 66 Profit Leaps 66 View Quick Facts 66 Hold Second Quarter 66 Reports Wider 66 Sees 4Q 66 Syneron logo 66 Orally Active 66 Cholesterol Drugs 66 Backs FY# 66 Finalizes Acquisition 66 Earnings Soar 66 Jointly Announce 66 Maintains Hold Rating 66 Positive Opinion 66 II Clinical Trial 66 Profits Climb 66 Lifts FY# EPS 66 Announce Second Quarter 66 Sees Upside 66 Achieves Significant 66 CEO Discusses F#Q# [002] 66 4Q Loss 66 Discuss Third Quarter 66 plc ELN 66 evaluating mipomersen 66 Report Initiates Independent 66 Inc SPPI 66 TRANSDUR ® 66 Increases Quick Facts 66 4Q Profit Rises 66 Patients Receiving 66 Settle Litigation 66 Announces Underwriters Exercise 66 Showcases Innovative 66 Patients Suffering 66 Schedules Webcast 66 Upside Looming 66 Upside Purchased 66 Corporation GENZ GENZ 66 Receives Approval From 66 Treatment Naïve 66 Reschedules Fourth Quarter 66 Restructures Operations 66 FDA APPROVES 66 Traders Hedging Bets 66 Reaffirms Earnings 66 Therapeutic Competitors Report 66 Stock Tumbles 66 Heartburn Drugs 66 Restate Results 66 developing adecatumumab 66 Profit Beats Expectations 66 Amigal TM 66 Profit Jumps 66 Profit Surges 66 Profit Doubles 66 Gets Favorable 66 2Q Profit 66 Outperforms 66 Guides FY# 66 Misses Estimates 66 Study Identifies 66 Announces Immediate Availability 66 Shows Statistically Significant 66 Chronic Hepatitis C 66 includes Dideco CarboMedics 66 Nasdaq HALO 66 Outlook Quick Facts 66 Commence Phase 66 4Q Profit 66 Phase 2a Clinical Trial 66 Completes Reorganization 66 Shares Tumble 66 FFO Rises 66 Acquire Assets 66 Lowers Forecast 66 Announces Consummation 66 MONSTERSTOX.COM Monsterstox.com 66 Consummates 66 Edges Higher 66 Abstract Accepted 66 Webcast Presentation 66 Nasdaq AVNC 66 Raises Dividend 66 Teva Provides Update 66 NYSE PFE Exelon Rivastigmine 66 Announces Cancellation 66 CEO Discusses Q1 66 Citi Downgrades 66 Misses Views 66 Nasdaq MNKD focuses 66 Announces Share Repurchase 66 Projected Release Date 66 Files Patent 66 combines bupropion 66 visit www.noven.com 66 Schaeffer Sentiment Snapshot 66 Completes Buyout 66 Adopts Shareholder Rights 66 Reports Double Digit 66 Swings To 66 FDA Approves Novel 66 2Q Profit Falls 66 Put Volume Surges 66 PharmaVitae Profile 66 Amylin Pharma 66 Profit Increases 66 Profit Declines 66 Holds Annual Meeting 66 Treatment Reduces 66 Introduces Innovative 66 1Q Profit Down 66 Boosts Buyback 66 Revises Q3 66 Shingles Vaccine 66 Jefferies Raises 66 Kinase Inhibitor 66 Lowers 4Q 66 Announce Third Quarter 66 Introduces Breakthrough 66 Announces Effective Date 66 Webcast Third Quarter 66 Technicals Showing Bearish 66 Raises Bid 66 Successfully Treats 66 PROVENGE ® 66 Given Outperform Rating 66 Better Than Expected 66 Profit Soars 66 Prove Effective 66 please visit www.eisai.com 66 Helps Reduce 66 UBS Maintains Buy 66 NASDAQ BMRN 66 Adopts Stockholder Rights 66 HOT STOCKS 66 Shareholders Approve Sale 66 Q3 Profit Climbs 66 REG1 Anticoagulation System 66 3Q Profit Down 66 Subsidiary Enters 66 Receives Certification 66 4Q Profit Slides 66 Bullish Engulfing Formed 66 Widens Quick Facts 66 Q3 Profit Jumps 66 Unveils Groundbreaking 66 Oral Fingolimod 66 Company LLY LLY 66 Receives Notice Regarding 66 Profit Climbs 66 Complimentary Analyst Research 66 Tops Consensus 66 Completes Acquisitions 66 Demonstrates Sustained 66 Novel Antibiotic 66 Rating Maintained 66 Improved Survival 66 Demonstrated Significant 66 Statistically Significant 66 Transcept Pharmaceuticals 66 Settles Patent Suit 66 Gets Clearance 66 Posts 2Q Loss 66 Preclinical Models 66 Reversal Soon 66 Analyst Downgrade 66 Launches Unique 66 Tibotec BVBA 66 Posts Record 66 Gets Subpoena 66 Third Quarter Profit Rises 65 proprietary intravenous formulation 65 Winning Streak Continues 65 Mg Usa 65 LSE SHP.L 65 1Q Profit Climbs 65 Nasdaq SLXP 65 Raises Estimates 65 Relapsed Multiple Myeloma 65 Co. Initiates Independent 65 Declines Quick Facts 65 Neutral Analyst Blog 65 Completes Divestiture 65 Raises Quarterly Dividend 65 Files Definitive Proxy 65 UBS Downgrades 65 Little Colds Decongestant Plus